Praxis(US:PRAX)2026-02-19 14:02Financial Data and Key Metrics Changes - In Q4 2025, operating expenses totaled $97 million, up from $71.4 million in Q4 2024, with R&D expenses increasing from $56.3 million to $77.5 million and G&A expenses rising from $15.1 million to $19.5 million [17][18] - For the full year 2025, operating expenses reached $326 million, compared to $209 million in 2024, driven by increased spending on clinical programs [17][18] - The company ended Q4 2025 with $926 million in cash and equivalents, a significant increase from $469 million at the end of 2024, bolstered by proceeds from public offerings [18][19] Business Line Data and Key Metrics Changes - The ulixacaltamide program reported positive results from the Essential3 program, leading to an NDA submission for essential tremor, with a potential market of over $10 billion annually [9][10] - The relutrigine program for SCN2A and SCN8A DEEs has an initial addressable population of approximately 10,000 patients, with potential annual revenue estimated at $5 billion [12] - Vormatrigine demonstrated a 58% reduction in seizures at week 1 in the RADIANT phase 2 study, with potential annual revenue exceeding $4 billion [14] Market Data and Key Metrics Changes - The addressable population for ulixacaltamide in the U.S. is estimated at 2 million patients with essential tremor, while the broader DEE population for relutrigine is over 200,000 patients [9][12] - The company is preparing for a significant commercial launch, focusing on disease awareness and inventory management for ulixacaltamide and relutrigine [22][31] Company Strategy and Development Direction - The company aims to transform into a commercial entity, with plans to submit two NDAs and enhance its clinical portfolio in 2026 [5][6] - A comprehensive medical education campaign is planned for the upcoming American Academy of Neurology annual meeting to raise awareness about ulixacaltamide [10][25] - The company is focused on building a strong commercial organization and ensuring sufficient inventory for product launches [22][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the potential for multiple readouts from the clinical pipeline and the importance of executing pre-commercial activities [16][17] - The company is well-capitalized with a strong balance sheet, expecting to fund operations into 2028 [19] - Management emphasized the importance of understanding the competitive landscape and the unmet needs in CNS disorders [10][12] Other Important Information - The company is planning an R&D day to discuss clinical programs and a commercial day to highlight launch strategies for ulixacaltamide and relutrigine [16] - Elsunersen is being developed for a rare genetic epilepsy, with a potential NDA submission expected next year [15][16] Q&A Session Summary Question: Can you walk us through the pre-commercial activities and cadence throughout 2026? - The company is making key hires and building inventory for strong launches, focusing on disease awareness for ulixacaltamide [22] Question: What additional new data can we expect at AAN? - The company will present about 15 different presentations, focusing on the Essential3 program and clinical data [25] Question: What is the status of alternative titration schedules for ulixacaltamide? - The company has proposed alternative titration schedules to the FDA and is awaiting their decision [29] Question: How much capital allocation should be expected between relutrigine and ulixacaltamide? - More allocation is expected for ulixacaltamide due to its broader market potential [31] Question: What is the review timeline for the NDAs? - The company has requested priority review for relutrigine but not for ulixacaltamide, considering strategic business reasons [43][44] Question: Can we expect long-term follow-up data at AAN? - The company plans to present long-term efficacy data to reinforce the value of ulixacaltamide [51] Question: What are the expectations for the EMBRAVE study? - The EMBRAVE study is expected to provide valuable data, with a focus on safety and efficacy [81][84]